Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.51 |
| ▸ | LPL | P06858 | 7/20 | 0.51 |
| ▸ | F11 | P03951 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | P4HB | P07237 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27635300 | 0.86 | F2 (0.46) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL534958 | 0.81 | NPSR1 (0.39) | LIPGLPLRCE1L3MBTL1MEN1 | |
| SCHEMBL17468510 | 0.79 | P4HB (0.44) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL12031512 | 0.79 | LIPG (0.59) | LIPGLPLF11P4HB | |
| SCHEMBL7228409 | 0.78 | MEN1 (0.61) | RCE1CA1CA2L3MBTL1CA12 | |
| SCHEMBL2718768 | 0.78 | LIPG (0.52) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL16247340 | 0.78 | P4HB (0.51) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL2595120 | 0.78 | LIPG (0.52) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL410785 | 0.77 | LIPG (0.51) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL1684669 | 0.76 | LIPG (0.53) | LIPGLPLF11F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629366-B2 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20060100252-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-7037938-B2 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20040006143-A1 | For therapy of urinary incontinence | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100252-A1 | Aminoalcohol derivatives | H1-0, CHRM2, CHRM1 | LIPG 3791/4885LPL 4015/4885F11 567/4885 |
| US-20040006143-A1 | For therapy of urinary incontinence | H1-0, HRH2, H1-2 | LIPG 4786/4885LPL 4774/4885F11 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.